Please use this identifier to cite or link to this item:
Title: Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis
Authors: Shamshirian, A.
Aref, A.R.
Yip, George W. 
Ebrahimi Warkiani, M.
Heydari, K.
Razavi Bazaz, S.
Hamzehgardeshi, Z.
Shamshirian, D.
Moosazadeh, M.
Alizadeh-Navaei, R.
Keywords: Breast neoplasm
Serum HER-2
Issue Date: 2020
Publisher: BioMed Central Ltd
Citation: Shamshirian, A., Aref, A.R., Yip, George W., Ebrahimi Warkiani, M., Heydari, K., Razavi Bazaz, S., Hamzehgardeshi, Z., Shamshirian, D., Moosazadeh, M., Alizadeh-Navaei, R. (2020). Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis. BMC Cancer 20 (1) : 1049. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Background: Measurement of serum human epidermal growth factor receptor-2 (HER-2/neu) levels might play an essential role as a diagnostic/screening marker for the early selection of therapeutic approaches and predict prognosis in breast cancer patients. We aimed to undertake a systematic review and meta-analysis focusing on the diagnostic/screening value of serum HER-2 levels in comparison to routine methods. Methods: We performed a systematic search via PubMed, Scopus, Cochrane-Library, and Web of Science databases for human diagnostic studies reporting the levels of serum HER-2 in breast cancer patients, which was confirmed using the histopathological examination. Meta-analyses were carried out for sensitivity, specificity, accuracy, area under the ROC curve (AUC), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR). Results: Fourteen studies entered into this investigation. The meta-analysis indicated the low sensitivity for serum HER2 levels (Sensitivity: 53.05, 95%CI 40.82–65.28), but reasonable specificity of 79.27 (95%CI 73.02–85.51), accuracy of 72.06 (95%CI 67.04–77.08) and AUC of 0.79 (95%CI 0.66–0.92). We also found a significant differences for PPV (PPV: 56.18, 95%CI 44.16–68.20), NPV (NPV: 76.93, 95%CI 69.56–84.31), PLR (PLR: 2.10, 95%CI 1.69–2.50) and NLR (NLR: 0.58, 95%CI 0.44–0.71). Conclusion: Our findings revealed that although serum HER-2 levels showed low se nsitivity for breast cancer diagnosis, its specificity, accuracy and AUC were reasonable. Hence, it seems that the measurement of serum HER-2 levels can play a significant role as a verification test for initial negative screening test results, especially in low-income regions due to its cost-effectiveness and ease of implementation. © 2020, The Author(s).
Source Title: BMC Cancer
ISSN: 1471-2407
DOI: 10.1186/s12885-020-07545-2
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s12885_020_07545_2.pdf1.88 MBAdobe PDF




checked on May 21, 2022


checked on Oct 5, 2021

Page view(s)

checked on May 12, 2022

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons